National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
The aim of this study was to analyze the extended spectrum of β lactamase (ESBL), metallo β lactamase (MBL) and AmpC production in Pseudomonas aeruginosa in various clinical samples. A Total of 100 clinical isolates of P. aeruginosa were collected from different clinical specimen and confirmed by standard tests. Antibiotic susceptibility was determined by the Kirby-Bauer disc diffusion method. ESBL screening was done using 3rd generation cephalosporins and confirmatory combined double disc test, imipenem-EDTA double disc synergy test for MBL enzyme and AmpC test using Cefoxitin disc. Out of 100 clinical P.aeruginosa isolates, 33% were ESBL producer, 18 % MBL producer both ESB and MBL 9% and none were AmpC producer. Imipenem (81%), meropenem (82%), aminoglycosides (amikacin (72%), tobramycin (74%), netilmycin (71%) and Polymyxin B(100%) and colistin (100%) has got the better antipseudomonal activity. 28 (28%) P.aeruginosa was found to be Multi Drug Resistant (MDR). This study highlights the prevalence of ESBL, MBL and MDR P.aeruginosa. In our study Carbapenems and aminoglycosides are promising drugs with antipseudomonal activity while polymyxin b and colstin use as reserved drug.
Citations |
 |
 |
 |
 |
